¹H and ³¹P metabolites of the tumor site and the control tissue of patients with rGBMs before and 8 weeks after start of BVZ treatment (mean and SD).

Patients were separated in two groups: patients with long-term survival-time (OS) and patients with short-term OS referring to the median survival days of the whole patient cohort. Significant differences between tumor and controls are marked in bold (p<0.05) and 8 weeks after onset of BVZ treatment are marked in italic.